

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifiers

Product name : Avutometinib

Product Number : 10-1064

Brand : Focus Biomolecules CAS-No. : 946128-88-7

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses : For Laboratory Research Use Only

1.3 Details of the supplier of the safety data sheet

Company : Focus Biomolecules

400 Davis Drive, Suite 600 Plymouth Meeting, PA 19462

Telephone : +1 855-362-8721

E-mail : support@focusbiomolecules.com

1.4 Emergency telephone number

Emergency Phone # : CHEMTREC within USA/Canada 1-800- 424-9300

CHEMTREC outside USA/Canada 1-703-527-3887

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)

Acute toxicity (Category 4), H302 Skin irritation (Category 2), H315 Eye irritation (Category 2A), H319

Specific target organ toxicity - single exposure (Category 3), Respiratory system, H335

For the full text of the H-Statements mentioned in this Section, see Section 16. 2.2

GHS Label elements, including precautionary statements

Avutometinib Page 1 of 8

Pictogram



Signal word Warning

Hazard statement(s)

H302 Harmful if swallowed H315 Causes skin irritation.

H319 Causes serious eye irritation.
H335 May cause respiratory irritation.

Precautionary statement(s)

P261 Avoid breathing dust/ fume/ gas/ mist/ vapors/ spray.

P264 Wash skin thoroughly after handling.

P271 Use only outdoors or in a well-ventilated area.

P280 Wear protective gloves/ eye protection/ face protection.
P302 + P352 IF ON SKIN: Wash with plenty of soap and water.

P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable

for breathing. Call a POISON CENTER/doctor if you feel

P305 + P351 + P338 unwell. IF IN EYES: Rinse cautiously with water for several

minutes. Remove contact lenses, if present and easy to do.

Continue rinsing.

P332 + P313 If skin irritation occurs: Get medical advice/ attention.
P337 + P313 If eye irritation persists: Get medical advice/ attention.
P362 Take off contaminated clothing and wash before reuse.

P403 + P233 Store in a well-ventilated place. Keep container tightly closed.

P405 Store locked up.

P501 Dispose of contents/ container to an approved waste disposal

plant.

2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none

SECTION 3: Composition/information on ingredients

3.1 Substances

Formula : $C_{21}H_{18}FN_5O_5S$ Molecular weight : 471.46 g/molCAS-No. : 946128-88-7EC-No. : N/A

Component	Classification	Concentration			
Avutometinib					
	Acute tox 4;Skin Irrit. 2; Eye Irrit. STOT SE 3; H302, H315, H319, H				

For the full text of the H-Statements mentioned in this Section, see Section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

Avutometinib Page 2 of 8

General advice

Consult a physician. Show this safety data sheet to the doctor in attendance. Move out of dangerous area.

If inhaled

If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.

In case of skin contact

Wash off with soap and plenty of water. Consult a physician.

In case of eye contact

Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.

If swallowed

Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.

4.2 Most important symptoms and effects, both acute and delayed

The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3 Indication of any immediate medical attention and special treatment needed No data available

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media

Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

5.2 Special hazards arising from the substance or mixture Carbon oxides,

Nitrogen oxides (NOx), sulfur oxides, Hydrogen fluoride

5.3 Advice for firefighters

Wear self-contained breathing apparatus for firefighting if necessary.

5.4 Further information

No data available

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust. For personal protection see section 8.

6.2 Environmental precautions

Do not let product enter drains.

6.3 Methods and materials for containment and cleaning up

Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for disposal.

Avutometinib Page 3 of 8

6.4 Reference to other sections

For disposal see section 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Further processing of solid materials may result in the formation of combustible dusts. The potential for

combustible dust formation should be taken into consideration before additional processing occurs.

Provide appropriate exhaust ventilation at places where dust is formed.

For precautions see section 2.2.

7.2 Conditions for safe storage, including any incompatibilities

Keep container tightly closed in a dry and well-ventilated place.

Recommended storage temperature -20°C

Store with desiccant. Light sensitive.

Storage class (TRGS 510): 11: Non-combustible

Solids

7.3 Specific end use(s)

Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Components with workplace control parameters

Contains no substances with occupational exposure limit values.

8.2 Exposure controls

Appropriate engineering controls

Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday.

Personal protective equipment

Eye/face protection

Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).

Skin protection

Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands.

Body Protection

Impervious clothing, The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.

Respiratory protection

For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator. For higher level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or

Avutometinib Page 4 of 8

CEN (EU).

Control of environmental exposure

Do not let product enter drains.

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

a)	Appearance	Form: solid
b)	Odor	No data available
c)	Odor Threshold	No data available
d)	рН	No data available
e)	Melting point/freezing point	No data available
f)	Initial boiling point and boiling range	No data available
g)	Flash point	No data available
h)	Evaporation rate	No data available
i)	Flammability (solid, gas)	No data available
j)	Upper/lower flammability or explosive limits	No data available
k)	Vapor pressure	No data available
l)	Vapor density	No data available
m)	Relative density	No data available
n)	Water solubility	No data available
0)	Partition coefficient: n-octanol/water	No data available
p)	Auto-ignition temperature	No data available
q)	Decomposition temperature	No data available
r)	Viscosity	No data available
s)	Explosive properties	No data available
t)	Oxidizing properties	No data available

9.2 Other safety information

No data available

Avutometinib Page 5 of 8

SECTION 10: Stability and reactivity

10.1 Reactivity

No data available

10.2 Chemical stability

Stable under recommended storage conditions.

10.3 Possibility of hazardous reactions

No data available

10.4 Conditions to avoid

No data available

10.5 Incompatible materials

No data available

10.6 Hazardous decomposition products

Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen oxides (NOx), sulfur oxides, Hydrogen fluoride

Other decomposition products - No data available

In the event of fire: see section 5

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Acute toxicity

Oral - No data available Inhalation: No data available Dermal: No data available

Skin corrosion/irritation

No data available

Serious eye damage/eye irritation

No data available

Respiratory or skin sensitisation

No data available

Germ cell mutagenicity

No data available

Carcinogenicity

IARC: No component of this product present at levels greater than or equal to 0.1% is identified as

probable, possible or confirmed human carcinogen by IARC.

NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a known

or anticipated carcinogen by NTP.

OSHA: No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of

regulated carcinogens.

Reproductive toxicity

No data available

Specific target organ toxicity - single exposure Inhalation -

Avutometinib Page 6 of 8

Specific target organ toxicity - repeated exposure

No data available

Aspiration hazard

No data available

Additional Information

RTECS: N/A

SECTION 12: Ecological information

12.1 Toxicity

No data available

12.2 Persistence and degradability

No data available

12.3 Bioaccumulative potential

No data available

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product

Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste disposal service to dispose of this material.

Contaminated packaging

Dispose of as unused product.

SECTION 14: Transport information

DOT (US)

Not dangerous goods

IMDG

Not dangerous goods

IATA

Not dangerous goods

Avutometinib Page 7 of 8

SECTION 15: Regulatory information

SARA 302 Components

No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.

SARA 313 Components

This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

SARA 311/312 Hazards

Acute Health Hazard

Massachusetts Right To Know Components

No components are subject to the Massachusetts Right to Know Act.

No components are subject to the Massachusetts Right to Know Act.

Pennsylvania Right To Know Components

Avutometinib	CAS-No. 946128-88-7	Revision Date
Avutometinib	CAS-No. 946128-88-7	Revision Date
New Jersey Right To Know Components Avutometinib	CAS-No.	Revision Date

946128-88-7

SECTION 16: Other information

Further information

Copyright 2025 Focus Biomolecules. License granted to make unlimited paper copies for internal use only. The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. Materials are intended for Laboratory Use only and must be used by qualified technicians. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. Focus Biomolecules and its Affiliates shall not be held liable for any damage resulting from handling or from contact with the above product.

Avutometinib Page 8 of 8

Version: 1.0 Revision Date: 04/29/2025

Avutometinib Page 8 of 8